Prostaglandin E2 induces CYP1B1 expression via ligand-independent activation of the ERα pathway in human breast cancer cells

Toxicological Sciences

Volumn 114, Issue 2, 2010, Pages 204-216

  Han, Eun H ^a,b   Kim, Hyung G ^a,b   Hwang, Young P ^a,c   Song, Gye Yong ^a   Jeong, Hye G ^a  

^a Chungnam National University   (South Korea)

^b Chosun University   (South Korea)

^c Chonnam National University   (South Korea)

Author keywords

Cyclooxygenase 2; CYP1B1; ERa; Prostaglandin E2

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 2; CYTOCHROME P450 1B1; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MITOGEN ACTIVATED PROTEIN KINASE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; PROTEIN KINASE B; SERINE; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P 450 CYP1B1; CYTOCHROME P-450 CYP1B1; ESR1 PROTEIN, HUMAN; LIGAND; MESSENGER RNA; UNSPECIFIC MONOOXYGENASE;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; ESTROGEN RESPONSIVE ELEMENT; GENE EXPRESSION; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; BIOSYNTHESIS; BREAST TUMOR; ENZYME INDUCTION; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TUMOR CELL LINE;

ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; ENZYME INDUCTION; ESTROGEN RECEPTOR ALPHA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LIGANDS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER;

EID: 77951567623     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfq013     Document Type: Article

References (56)

1. Beato, M., and Klug, J. (2000). Steroid hormone receptors: an update. Hum. Reprod. Update 6, 225-236.
2. Berthois, Y., Katzenellenbogen, J. A., and Katzenellenbogen, B. S. (1986). Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc. Natl. Acad. Sci. U.S.A. 83, 2496-2500.
3. Breyer, M. D., and Breyer, R. M. (2000). Prostaglandin E receptors and the kidney. Am. J. Physiol. Renal Physiol. 279, F12-F23.
4. Bugano, D. D., Conforti-Froes, N., Yamaguchi, N. H., and Baracat, E. C. (2008). Genetic polymorphisms, the metabolism of estrogens and breast cancer: a review. Eur. J. Gynaecol. Oncol. 29, 313-320.
5. Cavalieri, E., Chakravarti, D., Guttenplan, J., Hart, E., Ingle, J., Jankowiak, R., Muti, P., Rogan, E., Russo, J., Santen, R., et al. (2006). Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim. Biophys. Acta 1766, 63-78.
6. Cavalieri, E. L., Stack, D. E., Devanesan, P. D., Todorovic, R., Dwivedy, I., Higginbotham, S., Johansson, S. L., Patil, K. D., Gross, M. L., Gooden, J. K., et al. (1997). Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc. Natl. Acad. Sci. U.S.A. 94, 10937-10942.
7. Chen, D., Pace, P. E., Coombes, R. C., and Ali, S. (1999). Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Mol. Cell. Biol. 19, 1002-1015.
8. Clamp, A., Danson, S., and Clemons, M. (2002). Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies. Lancet Oncol. 3, 611-619.
9. Clemons, M., and Goss, P. (2001). Estrogen and the risk of breast cancer. N. Engl. J. Med. 344, 276-285.
10. Coumoul, X., Diry, M., Robillot, C., and Barouki, R. (2001). Differential regulation of cytochrome P450 1A1 and 1B1 by a combination of dioxin and pesticides in the breast tumor cell line MCF-7. Cancer Res. 61, 3942-3948.
11. Eliassen, A. H., Missmer, S. A., Tworoger, S. S., Spiegelman, D., Barbieri, R. L., Dowsett, M., and Hankinson, S. E. (2006). Endogenous steroid hormone concentrations and risk of breast cancer among pre-menopausal women. J. Natl. Cancer Inst. 98, 1406-1415.
12. Ellis, M. (2004). Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist 9(Suppl. 3), 20-26.
13. Enmark, E., and Gustafsson, J. A. (1999). Oestrogen receptors-an overview. J. Intern. Med. 246, 133-138.
14. Feng, W., Webb, P., Nguyen, P., Liu, X., Li, J., Karin, M., and Kushner, P. J. (2001). Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway. Mol. Endocrinol. 15, 32-45.
15. Gaikwad, N. W., Yang, L., Muti, P., Meza, J. L., Pruthi, S., Ingle, J. N., Rogan, E. G., and Cavalieri, E. L. (2008). The molecular etiology of breast cancer: evidence from biomarkers of risk. Int. J. Cancer 122, 1949-1957.
16. Gibson, P., Gill, J. H., Khan, P. A., Seargent, J. M., Martin, S. W., Batman, P. A., Griffith, J., Bradley, C., Double, J. A., Bibby, M. C., et al. (2003). Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. Mol. Cancer Ther. 2, 527-534.
17. Half, E., Tang, X. M., Gwyn, K., Sahin, A., Wathen, K., and Sinicrope, F. A. (2002). Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 62, 1676-1681.
18. Howe, L. R., Chang, S. H., Tolle, K. C., Dillon, R., Young, L. J., Cardiff, R. D., Newman, R. A., Yang, P., Thaler, H. T., Muller, W. J., et al. (2005). HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res. 65, 10113-10119.
19. Jefcoate, C. R., Liehr, J. G., Santen, R. J., Sutter, T. R., Yager, J. D., Yue, W., Santner, S. J., Tekmal, R., Demers, L., Pauley, R., et al. (2000). Tissue-specific synthesis and oxidative metabolism of estrogens. J. Natl. Cancer Inst. Monogr. 27, 95-112.
20. Johnston, S. R. (2005). Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clin. Cancer Res. 11, 889-899.
21. Katzenellenbogen, B. S., and Katzenellenbogen, J. A. (2000). Estrogen receptor transcription and transactivation: estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res. 2, 335-344.
22. Klinge, C. M. (2000). Estrogen receptor interaction with co-activators and co-repressors. Steroids 65, 227-251.
23. Kushner, P. J., Agard, D. A., Greene, G. L., Scanlan, T. S., Shiau, A. K., Uht, R. M., and Webb, P. (2000). Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 74, 311-317.
24. Lannigan, D. A. (2003). Estrogen receptor phosphorylation. Steroids 68, 1-9.
25. Liehr, J. G., and Ricci, M. J. (1996). 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc. Natl. Acad. Sci. U.S.A. 93, 3294-3296.
26. Likhite, V. S., Stossi, F., Kim, K., Katzenellenbogen, B. S., and Katzenellenbogen, J. A. (2006). Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonu-cleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol. Endocrinol. 20, 3120-3132.
27. Lin, P., Chang, H., Ho, W. L., Wu, M. H., and Su, J. M. (2003). Association of aryl hydrocarbon receptor and cytochrome P4501B1 expressions in human non-small cell lung cancers. Lung Cancer 42, 255-261.
28. Liu, C. H., Chang, S. H., Narko, K., Trifan, O. C., Wu, M. T., Smith, E., Haudenschild, C., Lane, T. F., and Hla, T. (2001). Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. 276, 18563-18569.
29. Loven, M. A., Wood, J. R., and Nardulli, A. M. (2001). Interaction of estrogen receptors alpha and beta with estrogen response elements. Mol. Cell Endocrinol. 181, 151-163.
30. McFadyen, M. C., Breeman, S., Payne, S., Stirk, C., Miller, I. D., Melvin, W. T., and Murray, G. I. (1999). Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J. Histochem. Cytochem. 47, 1457-1464.
31. Mestre, J. R., Subbaramaiah, K., Sacks, P. G., Schantz, S. P., Tanabe, T., Inoue, H., and Dannenberg, A. J. (1997). Retinoids suppress phorbol estermediated induction of cyclooxygenase-2. Cancer Res. 57, 1081-1085.
32. Michael, M. D., Michael, L. F., and Simpson, E. R. (1997). A CRE-like sequence that binds CREB and contributes to cAMP-dependent regulation of the proximal promoter of the human aromatase P450 (CYP19) gene. Mol. Cell. Endocrinol. 134, 147-156.
33. Murray, G. I., Taylor, M. C., McFadyen, M. C., McKay, J. A., Greenlee, W. F., Burke, M. D., and Melvin, W. T. (1997). Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 57, 3026-3031.
34. Muskhelishvili, L., Thompson, P. A., Kusewitt, D. F., Wang, C., and Kadlubar, F. F. (2001). In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues. J. Histochem. Cytochem. 49, 229-236.
35. Nilsson, S., Makela, S., Treuter, E., Tujague, M., Thomsen, J., Andersson, G., Enmark, E., Pettersson, K., Warner, M., and Gustafsson, J. A. (2001). Mechanisms of estrogen action. Physiol. Rev. 81, 1535-1565.
36. Petz, L. N., and Nardulli, A. M. (2000). Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor A promoter. Mol. Endocrinol. 14, 972-985.
37. Ristimaki, A., Sivula, A., Lundin, J., Lundin, M., Salminen, T., Haglund, C., Joensuu, H., and Isola, J. (2002). Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 62, 632-635.
38. Sassone-Corsi, P. (1998). Coupling gene expression to cAMP signalling: role of CREB and CREM. Int. J. Biochem. Cell Biol. 30, 27-38.
39. Saville, B., Wormke, M., Wang, F., Nguyen, T., Enmark, E., Kuiper, G., Gustafsson, J. A., and Safe, S. (2000). Ligand-, cell-, and estrogen receptor subtype (a/b)-dependent activation at GC-rich (Sp1) promoter elements. J. Biol. Chem. 275, 5379-5387.
40. Schrey, M. P., and Patel, K. V. (1995). Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Br. J. Cancer 72, 1412-1419.
41. Shah, Y. M., and Rowan, B. G. (2005). The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity. Mol. Endocrinol. 19, 732-748.
42. Shimada, T., Hayes, C. L., Yamazaki, H., Amin, S., Hecht, S. S., Guengerich, F. P., and Sutter, T. R. (1996). Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res. 56, 2979-2984.
43. Sissung, T. M., Price, D. K., Sparreboom, A., and Figg, W. D. (2006). Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol. Cancer Res. 4, 135-150.
44. Spink, D. C., Spink, B. C., Cao, J. Q., DePasquale, J. A., Pentecost, B. T., Fasco, M. J., Li, Y., and Sutter, T. R. (1998). Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis 19, 291-298.
45. Spivack, S. D., Hurteau, G. J., Reilly, A. A., Aldous, K. M., Ding, X., and Kaminsky, L. S. (2001). CYP1B1 expression in human lung. Drug Metab. Dispos. 29, 916-922.
46. Surowiak, P., Materna, V., Matkowski, R., Szczuraszek, K., Kornafel, J., Wojnar, A., Pudelko, M., Dietel, M., Denkert, C., Zabel, M., et al. (2005). Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res. 7, R862-R870.
47. Sutter, T. R., Tang, Y. M., Hayes, C. L., Wo, Y. Y., Jabs, E. W., Li, X., Yin, H., Cody, C. W., and Greenlee, W. F. (1994). Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J. Biol. Chem. 269, 13092-13099.
48. Swedenborg, E., Ruegg, J., Hillenweck, A., Rehnmark, S., Faulds, M. H., Zalko, D., Pongratz, I., and Pettersson, K. (2008). 3-Methylcholanthrene displays dual effects on estrogen receptor (ER) alpha and ER beta signaling in a cell-type specific fashion. Mol. Pharmacol. 73, 575-586.
49. Tamimi, R. M., Byrne, C., Colditz, G. A., and Hankinson, S. E. (2007). Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. 99, 1178-1187.
50. Timoshenko, A. V., Chakraborty, C., Wagner, G. F., and Lala, P. K. (2006). COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br. J. Cancer 94, 1154-1163.
51. Tsuchiya, Y., Nakajima, M., Kyo, S., Kanaya, T., Inoue, M., and Yokoi, T. (2004). Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res. 64, 3119-3125.
52. Yager, J. D., and Davidson, N. E. (2006). Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 354, 270-282.
53. Yue, W., Santen, R. J., Wang, J. P., Li, Y., Verderame, M. F., Bocchinfuso, W. P., Korach, K. S., Devanesan, P., Todorovic, R., Rogan, E. G., et al. (2003). Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J. Steroid Biochem. Mol. Biol. 86, 477-486.
54. Zhang, Z., Lundeen, S. G., Slayden, O., Zhu, Y., Cohen, J., Berrodin, T. J., Bretz, J., Chippari, S., Wrobel, J., Zhang, P., et al. (2007). In vitro and in vivo characterization of a novel nonsteroidal, species-specific progesterone receptor modulator, PRA-910. Ernst Schering Found. Symp. Proc. 1, 171-197.
55. Zhao, Y., Agarwal, V. R., Mendelson, C. R., and Simpson, E. R. (1996). Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137, 5739-5742.
56. Zhong, L., and Skafar, D. F. (2002). Mutations of tyrosine 537 in the human estrogen receptor-alpha selectively alter the receptor's affinity for estradiol and the kinetics of the interaction. Biochemistry 41, 4209-4217.